Pathophysiology of migraine: A role for neuropeptides

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 3, 2006, Pages 327-333

  Just, Stefan ^a   Arndt, Kirsten ^a   Weiser, Thomas ^a   Doods, Henri ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ADX 10059; ANALGESIC AGENT; BGC 20 1531; BMS 488072; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; DIHYDROERGOTAMINE; ENDOTHELIN; ERGOT DERIVATIVE; FP 0011; GLUTAMATE RECEPTOR ANTAGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE; NEUROPEPTIDE Y; NGX 424; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OLCEGEPANT; PGN 1531; PLACEBO; POTASSIUM CHANNEL KCNQ2; RECEPTOR BLOCKING AGENT; SEROTONIN 1 AGONIST; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SUBSTANCE P; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1 BLOCKING AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE; VOFOPITANT;

ALLODYNIA; ANTIINFLAMMATORY ACTIVITY; AUTONOMIC NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; CLUSTER HEADACHE; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEADACHE; HUMAN; MENINGEAL ARTERY; MIGRAINE; MIGRAINE AURA; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; REVIEW; SPREADING CORTICAL DEPRESSION; TRIGEMINUS GANGLION; VASOCONSTRICTION; VASODILATATION;

EID: 33847241252     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.07.002     Document Type: Review

References (55)

1. Headache classification subcommitee of the IHS. Classification and WHO ICD-10NA Codes. Cephalalgia 24 (2004) 16-22
2. Gerth W.C., et al. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 19 (2001) 197-206
3. Lipton R.B., et al. Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. Headache: J. Head Face Pain 41 (2001) 646-657
4. Gallagher R. What do patients want from acute migraine treatment?. Cephalalgia 24 (2004) 8-15
5. Diener H.C., et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24 (2004) 947-954
6. Lipton R.B., and Stewart W.F. Acute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy?. Headache: J Head Face Pain 39 (1999) S20-S26
7. Krymchantowski A.V., et al. New and emerging prophylactic agents for migraine. CNS Drugs 16 (2002) 611-634
8. Goadsby P.J., et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28 (1990) 183-187
9. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat. Rev. Neurosci. 4 (2003) 386-398
10. Goadsby P.J., et al. Migraine - current understanding and treatment. N. Engl. J. Med. 346 (2002) 257-270
11. Raskin N.H., et al. Headache may arise from perturbation of brain. Headache 27 (1987) 416-420
12. Weiller C., et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1 (1995) 658-660
13. Welch K.M., et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache 41 (2001) 629-637
14. Tajti J., et al. Neuropeptide localization in the 'migraine generator' region of the human brainstem. Cephalalgia 21 (2001) 96-101
15. Sanchez-del-Rio M., and Reuter U. Migraine aura: new information on underlying mechanisms. Curr. Opin. Neurol. 17 (2004) 289-293
16. Ebersberger A., et al. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache?. Ann. Neurol. 49 (2001) 7-13
17. Bolay H., et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8 (2002) 136-142
18. Dreier J.P., et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura?. Brain 125 (2002) 102-112
19. Wahl M., et al. Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res. 637 (1994) 204-210
20. Goadsby P.J., et al. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23 (1988) 193-196
21. Sarchielli P., et al. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20 (2000) 907-918
22. Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen. Pharmacol. 30 (1998) 5-11
23. Williamson D.J., and Hargreaves R.J. Neurogenic inflammation in the context of migraine. Microsc. Res. Tech. 53 (2001) 167-178
24. Roon K.I., et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann. Neurol. 47 (2000) 238-241
25. Burstein R., et al. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev. Neurol. (Paris) 161 (2005) 658-660
26. Carr D.B., and Lipkowski A.W. Neuropeptides and pain. Agressologie 31 (1990) 173-177
27. Bellamy J.L., et al. Salivary Levels of CGRP and VIP in Rhinosinusitis and Migraine Patients. Headache: J. Head Face Pain 46 (2006) 24-33
28. Valenzuela R.F., et al. Migraine, but not subarachnoid haemorrhage, is associated with differentially increased NPY-like immunoreactivity in the CSF. J. Neurol. Sci. 173 (2000) 140-146
29. Barbanti P., et al. unilateral cranial autonomic symptoms in migraine. Cephalalgia 22 (2002) 256-259
30. Uddman R., et al. Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry. J. Auton. Nerv. Syst. 26 (1989) 69-75
31. Yanagisawa M., and Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol. Sci. 10 (1989) 374-378
32. Kanazawa F., et al. Expression of endothelin-1 in the brain and lung of rats exposed to permanent hypobaric hypoxia. Brain Res. 1036 (2005) 145-154
33. Gallai V., et al. Endothelin 1 in migraine and tension-type headache. Acta Neurol. Scand. 89 (1994) 47-55
34. Schilling L., et al. Endothelin-1-induced contraction and relaxation of isolated rat basilar artery: effect of the endothelium. J. Cardiovasc. Pharmacol. 26 Suppl. 3 (1995) S197-S199
35. Brandli P., et al. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64 (1996) 315-322
36. May A., et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67 (1996) 375-378
37. Hasselblatt M., et al. Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport 10 (1999) 423-425
38. Quartara L., and Maggi C.A. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 32 (1998) 1-49
39. May A., and Goadsby P.J. Substance P receptor antagonists in the therapy of migraine. Expert Opin. Investig. Drugs 10 (2001) 673-678
40. Diener H.C. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23 (2003) 183-185
41. Connor H.E., et al. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia 18 (1998) 392
42. Hill R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans?. Trends Pharmacol. Sci. 21 (2000) 244-246
43. Schindler M., et al. Identification of somatostatin sst2(a) receptor expressing neurones in central regions involved in nociception. Brain Res. 798 (1998) 25-35
44. Helmchen C., et al. Inhibition of spinal nociceptive neurons by microinjections of somatostatin into the nucleus raphe magnus and the midbrain periaqueductal gray of the anesthetized cat. Neurosci. Lett. 187 (1995) 137-141
45. Sarchielli P., et al. Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia 26 (2006) 409-415
46. Ichikawa H., et al. The somatostatin SST2A receptor in the rat trigeminal ganglion. Neuroscience 120 (2003) 807-813
47. Pawlak M., et al. Somatostatin reduces the meningeal arterial blood flow in the rat. Neuroscience Letters 276 (1999) 33-36
48. Goadsby P.J. New targets in the acute treatment of headache. Curr. Opin. Neurol. 18 (2005) 283-288
49. Geppetti P., et al. CGRP and migraine: neurogenic inflammation revisited. J. Headache Pain 6 (2005) 61-70
50. Goadsby P.J. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 65 (2005) 2557-2567
51. Lassen L.H., et al. CGRP may play a causative role in migraine. Cephalalgia 22 (2002) 54-61
52. Doods H., et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129 (2000) 420-423
53. Storer R.J., et al. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. 142 (2004) 1171-1181
54. Fischer M.J.M., et al. The Nonpeptide Calcitonin Gene-Related Peptide Receptor Antagonist BIBN4096BS Lowers the Activity of Neurons with Meningeal Input in the Rat Spinal Trigeminal Nucleus. J. Neurosci. 25 (2005) 5877-5883
55. Olesen J., et al. Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. N. Engl. J. Med. 350 (2004) 1104-1110